New Drug Application (NDA)
A New Drug Application (NDA) is the formal submission a sponsor files with the U.S. Food and Drug Administration seeking approval to market a new small-molecule drug, compiling clinical trial safety and efficacy data, manufacturing details, and proposed labeling.
What is a New Drug Application (NDA)?
A New Drug Application (NDA) is the formal request a sponsor submits to the U.S. Food and Drug Administration seeking permission to market a new small-molecule drug. It assembles the full body of evidence the agency needs to judge whether the drug is safe and effective for its intended use.
The application brings together clinical trial results on safety and efficacy, detailed information on how the drug is manufactured and controlled, and proposed labeling describing approved uses and warnings. The FDA reviews this package before deciding whether to approve the product.
Why is the NDA important in regulatory practice?
The NDA is the central gatekeeping step that determines whether a new chemical drug can legally reach U.S. patients. Its completeness and quality shape the review timeline and the conditions of any eventual approval.
For drug developers, preparing an NDA represents the culmination of years of research and investment, and its outcome carries major commercial consequences. The process parallels but differs from the Biologics License Application used for biologic products, reflecting the distinct nature of small-molecule drugs.
- new drug application
- what is an nda
- nda fda
- nda submission
- new drug application meaning
- nda definition
- fda new drug application